Developing new medicines to treat atherosclerotic cardiovascular disease (ASCVD), the leading cause of death in the United States and in Europe, has never been more challenging (1) . The number of new drug approvals is down, whereas the cost of developing a new medicine is increasing. Many new drugs fail in the clinic because of efficacy, that is, the drug does not reduce risk for ASCVD when tested in humans.
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To overcome these challenges, the pharmaceutical industry is urgently searching for 2 solutions: "validated" gene targets and biomarkers that predict cardiovascular outcomes in a clinical trial (1, 2) . The term "validated" generally refers to increased confidence that targeting the gene will reduce risk of disease in humans. In addition to a validated gene target, the drug development process requires a biomarker that can help assess drug efficacy, dose-find in early clinical development, and predict disease risk.
Over the last 3 decades, the biomedical research community has intensively studied a specific gene target-CETP-and a related biomarker-high-density lipoprotein (HDL)-for their potential in altering risk for ASCVD (3, 4) . Studies in cellular models, animal models, and humans have led to 2 hypotheses. The first, the cholesteryl ester transfer protein (CETP) hypothesis, is focused on CETP as a gene target and suggests that: 1) increased enzymatic activity of CETP promotes atherosclerosis; and 2) inhibition of CETP activity will reduce risk for ASCVD (3) . The second, the HDL hypothesis, is focused on HDL as a biomarker and suggests that: 1) lower levels of HDL (as measured by the cholesterol content in HDL) increase risk for ASCVD; and 2) therapies that raise HDL will lower risk for ASCVD (4) . Despite considerable research, the answers to both hypotheses remain unsettled, and in the last few years, several results have challenged prior assumptions.
Against this background, in this issue of the Journal, Johannsen et al. (5) use naturally occurring human genetic variation to address these research questions. They test the hypothesis that common genetic variation at the CETP gene relates to plasma lipids and risk for incident ASCVD. In 10,261 participants from the prospective Copenhagen City Heart Study, they genotype 2 common single nucleotide polymorphisms (CETP Ϫ629CϾA or rs1800775 and Taq1BGϾA or rs708272) that have previously been associated with decreased CETP mass and decreased CETP activity (6, 7) . They find that the alleles associated with lower CETP activity are associated with a range of lipid biomarkers including: 1) higher apolipoprotein A-I containing lipoproteins (as measured by HDL cholesterol); 2) lower apolipoprotein B-containing lipoproteins (as measured by low-density lipoprotein [LDL] cholesterol and triglycerides); and 3) lower plasma lipoprotein(a) ( Table 1) . They also test whether these polymorphisms associate with traits relevant to the side effects of pharmacological CETP inhibition and find no such associations.
Beyond enzymatic activity and biomarkers, genetics has a unique potential to offer insights into human disease endpoints (8) . As such, the investigators' primary question was whether these CETP polymorphisms associate with incident ASCVD and mortality. They find that the CETP alleles associated with intermediate endpoints (lower CETP activity, higher HDL cholesterol, lower LDL cholesterol, lower triglycerides, and lower lipoprotein(a)) are indeed associated with decreased risk for ASCVD and mortality. Overall, these robust findings confirm the observations reported in a meta-analysis from 2008 and 2 additional independent studies since then (Table 1) (7, 9, 10) .
What are the implications of this study for the CETP hypothesis and the HDL hypothesis? With regard to the CETP hypothesis, these genetic association results seem to "validate" CETP as a gene target and suggest that drugs that inhibit CETP activity (and produce a similar lipid profile as the gene variants) are likely to reduce risk for ASCVD in clinical trials.
If so, how do we make sense of the failure of 2 different CETP inhibitors-torcetrapib and dalcetrapib-to reduce risk for ASCVD in large randomized controlled trials? For torcetrapib, a leading possibility is off-target side effects. In the ILLUMINATE (Investigation of Lipid Level Management to Understand Its Impact in Atherosclerotic Events) randomized controlled trial involving 15,067 participants, torcetrapib increased HDL cholesterol by 72%, decreased LDL cholesterol by 25%, and decreased triglycerides by 9% (11) . However, torcetrapib also increased blood pressure and aldosterone level. On net, when compared with placebo, torcetrapib treatment increased risk for ASCVD by 25%.
If torcetrapib's failure is potentially due to off-target effects, how does one understand the recent failure of dalcetrapib, a compound that did not have effects on blood pressure or aldosterone levels (12)? The dal-OUTCOMES trial randomized Ͼ15,000 participants to test the hypothesis that CETP inhibition with dalcetrapib will reduce cardiovascular morbidity and mortality in patients with recent ACS. In May 2012, the data safety and monitoring board stopped the trial at a second interim analysis due to "lack of clinically meaningful efficacy" (13) . Dalcetrapib may have failed due to issues related to clinical trial design such as insufficient statistical power, insufficient duration of follow-up, and wrong study population. As the study findings remain to be published in a peer-reviewed journal, it is at present difficult to evaluate these considerations.
Beyond study design, dalcetrapib's failure may lie with something more fundamental, the fact that dalcetrapib raised HDL cholesterol in isolation. In contrast to other CETP inhibitors, dalcetrapib only alters 1 lipid fraction-HDL cholesterol (12) . In Phase II clinical trials, dalcetrapib raised HDL cholesterol by about 25% to 30% without significant effects on LDL cholesterol, triglycerides, or blood pressure (14) . The dal-OUTCOMES study investigators expected each 1 mg/dl increase in HDL cholesterol to lead to a 1.5% relative risk reduction in the primary ASCVD endpoint (14) . The average participant treated with dalcetrapib was expected to have HDL cholesterol increase from 40 to 51 mg/dl, and this increase was projected to correspond to a 15% reduction in risk for the primary ASCVD endpoint. Critically, these calculations rest on the validity of the HDL hypothesis-that higher HDL causally protects from risk for ASCVD.
However, several lines of human genetic evidence now suggest that the epidemiologic association of higher HDL cholesterol with lower risk for ASCVD may not reflect a causal relationship. First, lifelong low HDL cholesterol due to Mendelian mutations in 3 genes-ABCA1, APOA1, or LCAT-is not consistently associated with increased risk for ASCVD (reviewed in Vergeer et al. [4] ). Second, in the Copenhagen City Heart Study, carriers of loss-of-function mutations in ABCA1 had ϳ17 mg/dl lower HDL cholesterol but were not at increased risk for ASCVD (15) . Third, we recently reported that ϳ2.6% of individuals carry an HDL cholesterol-boosting variant in the endothelial lipase gene and despite having Genetic Variation at the CETP Gene, Plasma Lipids, and Risk for Atherosclerotic Cardiovascular Disease higher HDL cholesterol, these individuals did not have lower risk for myocardial infarction (10) . Finally, we evaluated 14 common variants that affected HDL cholesterol in isolation (without affecting other lipid fractions) and found that a genotype score crafted from these variants did not relate to risk for myocardial infarction (10) . So, dalcetrapib may have failed because it altered only a noncausal biomarker. When combined, the dalcetrapib clinical trial results and the human genetic findings summarized here cast doubt on the notion that raising HDL cholesterol in isolation will reduce risk for ASCVD. For several decades, the biomedical research community has assumed that if an intervention raises HDL cholesterol, then that intervention will reduce risk for ASCVD. Now, it seems prudent to rethink this assumption and re-evaluate the use of HDL cholesterol as a biomarker predictive of ASCVD in intervention studies.
In contrast with the HDL cholesterol biomarker, human genetic studies strongly suggest that both LDL cholesterol and plasma lipoprotein(a) cause ASCVD. Rare mutations that lead to extremely high LDL cholesterol consistently increase risk for ASCVD (16, 17) . About 3% of individuals carry an LDL cholesterollowering variant in the proprotein convertase subtilisin/ kexin type 9 gene, and these individuals are at lower risk for myocardial infarction (18 -20) . A genotype score crafted from 13 variants that affected LDL cholesterol in isolation was strongly associated with myocardial infarction risk (10) . In addition, polymorphisms that increase plasma lipoprotein(a) consistently confer increased risk for ASCVD (21) (22) (23) .
What are the implications of these data for the 2 CETP inhibitors-anacetrapib and evacetrapib-that remain in clinical development (24, 25) ? These CETP inhibitors do not seem to have off-target effects on blood pressure or aldosterone. The pattern of lipid effects for anacetrapib and evacetrapib (higher HDL cholesterol, lower LDL cholesterol, lower triglycerides, and lower lipoprotein(a)) mirrors that seen by Johannsen et al. for the 2 CETP variants that are associated with lower CETP activity and lower risk for ASCVD. As such, the work of Johannsen et al. increases confidence that anacetrapib and evacetrapib will successfully reduce risk for ASCVD.
By providing direct evidence in humans prior to a clinical trial, studies of genetic variation such as that of Johannsen et al. represent powerful approaches to validate gene targets and pinpoint causal biomarkers. CETP inhibition by anacetrapib and evacetrapib is likely to succeed. However, we have learned that any potential benefit clearly cannot be ascribed to the HDL biomarker per se. Insights from human genetics and the completed dalcetrapib trial suggest that the success of CETP inhibitors may be more related to their effect on LDL cholesterol and lipoprotein(a) rather than through HDL elevation.
